Indefinite Delivery Contract SPE2DR25D9113

The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide a comprehensive range of pharmaceutical products and medical supplies to support the medical needs of military healthcare facilities worldwide. The IDC, under the SPE2DB program, covers an extensive portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications.

This IDC contract was awarded as part of the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) solicitation, which aims to establish multiple regional contracts to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency, U.S. Coast Guard, and U.S. Naval Fleet. The PPV-G GEN V solicitation is an unrestricted, fully competitive acquisition with a total estimated value of $30.3 billion across a 30-month base period and three 30-month option periods. The contracts will be awarded on a regional basis, with at least three different contractors selected to ensure the DoD's resiliency and access to vital pharmaceuticals during times of contingency or natural disasters.